Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology test… Read more
Shin Nippon Biomedical Laboratories, Ltd. (SBLOF) - Total Liabilities
Latest total liabilities as of September 2025: $52.75 Billion USD
Based on the latest financial reports, Shin Nippon Biomedical Laboratories, Ltd. (SBLOF) has total liabilities worth $52.75 Billion USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shin Nippon Biomedical Laboratories, Ltd. - Total Liabilities Trend (2020–2025)
This chart illustrates how Shin Nippon Biomedical Laboratories, Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shin Nippon Biomedical Laboratories, Ltd. Competitors by Total Liabilities
The table below lists competitors of Shin Nippon Biomedical Laboratories, Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Forge Resources Corp.
OTCQB:FRGGF
|
USA | $3.71 Million |
|
Unibios Holdings S.A
AT:BIOSK
|
Greece | €11.66 Million |
|
Neogrid Participações S.A
SA:NGRD3
|
Brazil | R$135.18 Million |
|
HBL Corporation
KQ:452190
|
Korea | ₩8.68 Billion |
|
KAISA GROUP HLDGS
F:KG5
|
Germany | €244.45 Billion |
|
Lumbee Guaranty Bank
OTCQX:LUMB
|
USA | $474.61 Million |
|
Man Zai Industrial Co Ltd
TWO:4543
|
Taiwan | NT$767.12 Million |
|
Pappajack Bhd
KLSE:0242
|
Malaysia | RM89.58 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Shin Nippon Biomedical Laboratories, Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shin Nippon Biomedical Laboratories, Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shin Nippon Biomedical Laboratories, Ltd. (2020–2025)
The table below shows the annual total liabilities of Shin Nippon Biomedical Laboratories, Ltd. from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $52.33 Billion | +24.18% |
| 2024-03-31 | $42.14 Billion | +36.46% |
| 2023-03-31 | $30.88 Billion | +57.65% |
| 2022-03-31 | $19.59 Billion | -7.31% |
| 2021-03-31 | $21.13 Billion | -6.57% |
| 2020-03-31 | $22.62 Billion | -- |